MedDataToolVidaza is a medication used to treat certain types of blood disorders, including myelodysplastic syndromes in adults and juvenile myelomonocytic leukemia in children. It works by affecting the way cells grow and develop, helping to restore normal function to blood cells. The medication is given as an injection under the skin or through an IV, starting at a dose of 75 mg/m² daily for seven days, with a maximum dose that can be adjusted based on how well the patient responds and tolerates it. It is important to know that Vidaza should not be used in patients with advanced malignant liver tumors. Additionally, patients with kidney problems may need careful monitoring and dose adjustments, as the medication is processed through the kidneys.
✦
Uses
- Adult patients with myelodysplastic syndromes (MDS).
- Pediatric patients aged 1 month and older with Juvenile Myelomonocytic Leukemia (JMML).
◷
Dosage
- Adults: 75 mg/m2 daily for 7 days, repeat every 4 weeks.
- Pediatric JMML: 2.5 mg/kg for under 1 year or 75 mg/m2 for 1 year and older, daily for 7 days.
⚠
Side effects
Common
nauseaanemiavomitingdiarrheafatigue
Serious
renal toxicityhepatotoxicitytumor lysis syndrome
🛑
Warnings
⚠ Important warnings
- Do not substitute VIDAZA for oral azacitidine.
- Monitor for renal toxicity and adjust dosage as needed.
- Elderly patients may have increased risk of toxicity.
Ask about this drug
Answers pulled from the FDA label only.
Medical Disclaimer: This content is provided for informational and educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before taking any medication.
Data Source: Publicly available drug labeling information from the U.S. Food and Drug Administration (FDA).
Data Source: Publicly available drug labeling information from the U.S. Food and Drug Administration (FDA).